Abstract
Intraductal papillary-mucinous neoplasms of the pancreas show characteristic clinicopathological and molecular pathobiological features which are distinct from those of conventional ductal adenocarcinomas. Alterations of KRAS, AKT/PKB, CDKN2A, TP53, SMAD4, STK11/LKB1, and DUSP6, and other molecular alterations, including global expression studies as well as their clinical implications, are discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenocarcinoma, Mucinous / genetics*
-
Adenocarcinoma, Mucinous / metabolism
-
Adenocarcinoma, Mucinous / pathology
-
Adenocarcinoma, Papillary / genetics*
-
Adenocarcinoma, Papillary / metabolism
-
Adenocarcinoma, Papillary / pathology
-
Biomarkers, Tumor / genetics*
-
Biomarkers, Tumor / metabolism
-
Carcinoma, Pancreatic Ductal / genetics*
-
Carcinoma, Pancreatic Ductal / metabolism
-
Carcinoma, Pancreatic Ductal / pathology
-
DNA, Neoplasm / genetics*
-
Disease Progression
-
Dual Specificity Phosphatase 6 / genetics
-
Dual Specificity Phosphatase 6 / metabolism
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
Pancreatic Neoplasms / genetics*
-
Pancreatic Neoplasms / metabolism
-
Pancreatic Neoplasms / pathology
-
Prognosis
-
Smad4 Protein / genetics
-
Smad4 Protein / metabolism
Substances
-
Biomarkers, Tumor
-
DNA, Neoplasm
-
SMAD4 protein, human
-
Smad4 Protein
-
DUSP6 protein, human
-
Dual Specificity Phosphatase 6